Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008–2011

Journal of Geriatric Oncology - Tập 7 - Trang 15-23 - 2016
Kevin W. Su1, Jane Hall1,2, Pamela R. Soulos1,2, Maysa M. Abu-Khalaf1,3, Suzanne B. Evans1,3,4, Sarah S. Mougalian1,3, Charles E. Rutter1,4, Amy J. Davidoff1,3,5, Cary P. Gross1,2,3
1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Comprehensive Cancer Center and Yale University School of Medicine, Harkness Office Building, 367 Cedar Street, New Haven CT, 06510, United States
2Section of General Internal Medicine, Yale University School of Medicine, PO Box 208025, New Haven, CT 06520-8025, United States
3Yale Cancer Center, Yale University School of Medicine, PO Box 208028, New Haven, CT 06520-8028, United States
4Department of Therapeutic Radiology, Yale University School of Medicine, PO Box 208040, New Haven, CT 06520-8040, United States
5Yale School of Public Health, Yale University, 60 College Street, P.O. Box 208034, New Haven CT, 06520-8034, United States

Tài liệu tham khảo

Gennari, 2004, Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients, Cancer, 101, 1302, 10.1002/cncr.20535

Diab, 2000, Tumor characteristics and clinical outcome of elderly women with breast cancer, J Natl Cancer Inst, 92, 550, 10.1093/jnci/92.7.550

Early Breast Cancer Trialists' Collaborative G,, 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0

Hurria, 2011, Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 29, 3457, 10.1200/JCO.2011.34.7625

Du, 2002, Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer, J Clin Oncol, 20, 4636, 10.1200/JCO.2002.05.088

Barcenas, 2014, Risk of Hospitalization according to chemotherapy regimen in early-stage breast cancer, J Clin Oncol,, 32, 2010, 10.1200/JCO.2013.49.3676

Wildiers, 2007, Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology, Lancet Oncol, 8, 1101, 10.1016/S1470-2045(07)70378-9

Trosman, 2010, Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay, J Oncol Pract, 6, 238, 10.1200/JOP.000075

Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588

Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985

Ademuyiwa, 2011, The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort, Breast Cancer Res Treat, 126, 797, 10.1007/s10549-010-1329-6

Lo, 2010, Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, J Clin Oncol, 28, 1671, 10.1200/JCO.2008.20.2119

Partin, 2011, Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer, Ann Surg Oncol, 18, 3399, 10.1245/s10434-011-1698-z

Hornberger, 2005, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am J Manag Care, 11, 313

Reed, 2013, Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer, Genet Med, 15, 203, 10.1038/gim.2012.119

Oestreicher, 2005, The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma, Cancer, 104, 2054, 10.1002/cncr.21464

Chen, 2013, Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer, J Oncol Pract, 9, 182, 10.1200/JOP.2012.000638

Lund, 2012, 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome, Cancer, 118, 788, 10.1002/cncr.26180

Hassett, 2012, Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer, J Clin Oncol, 30, 2218, 10.1200/JCO.2011.38.5740

Haas, 2011, Genomic testing and therapies for breast cancer in clinical practice, J Oncol Pract, 7, e1s, 10.1200/JOP.2011.000299

Guth, 2013, Utilization of oncotype DX in an inner city population: race or place?, Int J Breast Cancer., 2013, 653805, 10.1155/2013/653805

Sheppard, 2015, Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients, Clin Breast Cancer, 15, e83-92, 10.1016/j.clbc.2014.11.011

Dinan, 2015, Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005–2009, JAMA Oncol, 1, 158, 10.1001/jamaoncol.2015.43

Enewold, 2015, Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy, Breast Cancer Res Treat, 15, 149, 10.1007/s10549-015-3366-7

Dinan, 2015, Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among Medicare beneficiaries with early-stage breast cancer, 2005-2009, JAMA Oncol, 1, 1098, 10.1001/jamaoncol.2015.2722

Smith, 2010, A method to predict breast cancer stage using Medicare claims, 7, 1

Elixhauser, 1998, Comorbidity measures for use with administrative data, Med Care, 36, 8, 10.1097/00005650-199801000-00004

Dartmouth Atlas of Health Care, 1998, The Dartmouth Institute for Health Policy and Clincial Practice

Giordano, 2012, Decline in the use of anthracyclines for breast cancer, J Clin Oncol, 30, 2232, 10.1200/JCO.2011.40.1273

Bouchardy, 2007, Older female cancer patients: importance, causes, and consequences of undertreatment, J Clin Oncol, 25, 1858, 10.1200/JCO.2006.10.4208

Gross, 2013, The cost of breast cancer screening in the Medicare population, JAMA Intern. Med., 173, 220, 10.1001/jamainternmed.2013.1397

Nelson, 2009, Screening for breast cancer: an update for the U.S. Preventive Services Task Force, Ann Intern Med, 151, 727, 10.7326/0003-4819-151-10-200911170-00009

Engstrom, 2011, NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement, J Natl Compr Canc Netw, 9, S1, 10.6004/jnccn.2011.0138

Cuzick, 2011, Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, 29, 4273, 10.1200/JCO.2010.31.2835

Smith, 2013, Recurrence score across the age spectrum: is there an age discrimination?, J Clin Oncol, 31

Steiner, 2013, Recurrence score results in elderly patients with estrogen receptor positive early breast cancer, J Geriatr Oncol, 4, S33, 10.1016/j.jgo.2013.09.023

Thông tin
Thông tin xuất bản

Journal of Geriatric Oncology

Tập 7

15-23

Thông tin tác giả